Report on the quality of life analysis from the phase III trial of pion versus photon radiotherapy in locally advanced prostate cancer.
This report examines the quality of life (QOL) of 215 patients entered into a randomised trial between pion and photon radiotherapy for prostate cancer at a single institution. The survival and local control results of the trial were equivalent in both arms. A modification of the Rotterdam Symptom Checklist (RSCL) was used to assess QOL. Global QOL, toxicity and physical scores were found to be worse in pion-treated patients at the end of treatment (P<0.001, P<0.001, and P=0.02 respectively). There are no long-term differences in the QOL of pion- versus photon-treated patients. Sexual function was a concern for patients even at baseline. There was a progressive loss of sexual interest and erectile function. There was a significant impact from hormonal therapy at relapse. Hormonal treatment produced a stepwise significant worsening in global QOL, particularly for physical and psychological domains.
Duncan
G G
GG
Radiation Oncology Program, British Columbia Cancer Agency, Vancouver Clinic, and University of British Columbia, 600 West 10th Avenue, Vancouver, Canada. gduncan@bccancer.bc.ca
Philips
N
N
Pickles
T
T
D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy* / Q000534:rehabilitation; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008651:Mesons / Q000627:therapeutic use*; D008875:Middle Aged; D017785:Photons / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000534:rehabilitation; D011594:Psychometrics; D011788:Quality of Life
D018931:Antineoplastic Agents, Hormonal